<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973086</url>
  </required_header>
  <id_info>
    <org_study_id>HP/190201/CITRUSLIM/BCMH</org_study_id>
    <nct_id>NCT03973086</nct_id>
  </id_info>
  <brief_title>To Assess the Efficacy of CitruSlim® on Body Composition as Well as Metabolic and Hormonal Factors in Overweight and Obese Individuals</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy of CitruSlim® on Body Composition as Well as Metabolic and Hormonal Factors in Overweight and Obese Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CitruSlim® can promote healthy weight loss by promoting anabolic state during weight loss&#xD;
      programs, prevent the body from storing fat, reduce appetites and maintain healthy&#xD;
      cholesterol and blood glucose level during weight loss program.&#xD;
&#xD;
      This study focuses to prove the efficacy and safety of the product in a population of&#xD;
      overweight and obese individual.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Actual">September 18, 2020</completion_date>
  <primary_completion_date type="Actual">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body fat percent Body Mass Index (kg/m2)</measure>
    <time_frame>16 weeks.</time_frame>
    <description>Assessed using DEXA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Lean Body Mass (g)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed using DEXA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Fat (%)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed using DEXA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fat Free Mass (g)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed using DEXA</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Citrus flavonone-O-glycosides (Low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Citrus flavonone-O-glycosides (High dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Microcrystaline Cellulose- 400mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citrus flavonone-O-glycosides- LD</intervention_name>
    <description>Low Dose of 200 mg</description>
    <arm_group_label>Citrus flavonone-O-glycosides (Low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citrus flavonone-O-glycosides- HD</intervention_name>
    <description>High Dose of 400 mg</description>
    <arm_group_label>Citrus flavonone-O-glycosides (High dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Microcrystalline Cellulose) of 400 mg</description>
    <arm_group_label>Microcrystaline Cellulose- 400mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female participants with the age of ≥18 and ≤ 60 years of age.&#xD;
&#xD;
          2. BMI of ≥25 - ≤ 35 kg/m2&#xD;
&#xD;
          3. Waist circumference:India: Men: &gt; 94 cm (37 inches), Women: &gt;80 cm (31.5 inches) USA:&#xD;
             Men: &gt; 102 cm (40 inches), Women: &gt;89 cm (35 inches)&#xD;
&#xD;
          4. Triglycerides &gt;150 mg/dL&#xD;
&#xD;
          5. Blood pressure: Systolic: ≥130 mm Hg and/or Diastolic: ≥85 mm Hg&#xD;
&#xD;
          6. Fasting blood glucose ≥ 100 mg/ dl&#xD;
&#xD;
          7. Low HDL level: Men: &lt; 40 mg/dL, Women: &lt; 50 mg/dL&#xD;
&#xD;
          8. Ready to give voluntary, written, informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants meeting any of the following criteria will be excluded from the trial:&#xD;
&#xD;
          1. Current smoker.&#xD;
&#xD;
          2. Inability to walk independently.&#xD;
&#xD;
          3. Presence of unstable, acutely symptomatic, or life-limiting illness.&#xD;
&#xD;
          4. Neurological conditions causing functional or cognitive impairments&#xD;
&#xD;
          5. Unwillingness or inability to be randomized to one of three intervention groups.&#xD;
&#xD;
          6. Bilateral hip replacements.&#xD;
&#xD;
          7. Exposure to any non-registered drug product within 3 months prior to the screening&#xD;
             visit.&#xD;
&#xD;
          8. Unable/unwillingness to complete study specific diaries (digital/paper-based).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reveal</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Glycosides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

